Abbott Agrees To Global Continuous Glucose Monitoring Litigation Settlement With Dexcom

ABBOTT PARK, Ill., Dec. 23, 2024 -- Abbott announced today it has reached an agreement with DexCom, Inc. to settle all outstanding patent disputes between the companies in cases related to continuous glucose monitoring products.

The agreement will result in the dismissal of all pending cases in courts and patent offices worldwide. It also includes a provision that the parties will not litigate patent, trade dress, and design rights disputes with each other for the next 10 years. There are no financial payments associated with the settlement from either Abbott or Dexcom.

Abbott considers this agreement a positive development, as it allows the company to fully focus on supporting people with diabetes with its technologies and services.

Details of the settlement are confidential.

About Abbott:

Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritionals and branded generic medicines. Our 114,000 colleagues serve people in more than 160 countries. Connect with us at www.abbott.com and on LinkedIn, Facebook, Instagram, X and YouTube.

For further information: Abbott Media: Kate Dyer, (224) 668-9965; Abbott Financial: Michael Comilla, (224) 668-1872